Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. Circassia sells its novel, market-leading NIOX¬ asthma management products directly to specialists in the United States, United Kingdom and Germany, and in a wide range of other countries through its network of partners. The Company recently established a collaboration with AstraZeneca in the US in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza¬, and has the US commercial rights to late-stage COPD product Duaklir¬.
CircassiaÍs development pipeline includes a range of respiratory medicines. The Company's lead asthma treatment targets substitution of GSK's Flixotide¬ pMDI and was approved in the UK. Circassia is also developing a direct substitute for Seretide¬ pMDI, and its pipeline includes a number of inhaled medicines for COPD, including single and combination dose products. For more information on Circassia please visit www.circassia.com.
- Company Name:Circassia
(View Trends)
-
Headquarters: (View Map)Oxford, United Kingdom
-
Biotechnology
-
200 - 500 employees
- 2692682 Global Rank
- 396807 United Kingdom
-
Search43.56%
-
Direct42.61%
-
Referrals7.57%
-
Mail6.26%
-
Display0.00%
-
Social0.00%
- United States 59.5%
- Carriers
- Life and Health
- BlueCross BlueShield